Progression of Pre-Existing Vitiligo during Secukinumab Treatment for Psoriasis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vitiligo has been considered an unexplained paradoxical phenomenon during biologics use. Herein, we report an adult case of progression of pre-existing vitiligo during secukinumab treatment for psoriasis, and we also examined the immunohistochemical changes in rela- tion to biologics use. He was being administered monthly secukinumab of 300 mg dose for 2 years, and all psoriatic lesions were cleared, but pre-existing hypopigmented lesions became more distinct and larger than before unlike when using adalimumab. A skin biopsy of the hypopigmented lesion showed loss of epidermal melanocytes and absence of gp100 immune activities, and he was finally diagnosed with progression of pre-existing vitiligo. Immunohistochemical staining of vitiligo lesion showed decrease in interleukin-17 and tu- mor necrosis factor-α and increase in CD8+ T cells, interferon-γ, and CXCL10 after the use of secukinumab. In this study, we suggest that biologics-induced cytokine imbalance play a critical role in vitiligo progression in patients with chronic inf lammatory diseases, includ- ing psoriasis.
Abstract
Vitiligo has been considered an unexplained paradoxical phenomenon during biologics use. Herein, we report an adult case of progression of pre-existing vitiligo during secukinumab treatment for psoriasis, and we also examined the immunohistochemical changes in rela- tion to biologics use. He was being administered monthly secukinumab of 300 mg dose for 2 years, and all psoriatic lesions were cleared, but pre-existing hypopigmented lesions became more distinct and larger than before unlike when using adalimumab. A skin biopsy of the hypopigmented lesion showed loss of epidermal melanocytes and absence of gp100 immune activities, and he was finally diagnosed with progression of pre-existing vitiligo. Immunohistochemical staining of vitiligo lesion showed decrease in interleukin-17 and tu- mor necrosis factor-α and increase in CD8+ T cells, interferon-γ, and CXCL10 after the use of secukinumab. In this study, we suggest that biologics-induced cytokine imbalance play a critical role in vitiligo progression in patients with chronic inf lammatory diseases, includ- ing psoriasis.
참고문헌 (12)
- Dong J, "New biologics in psoriasis : an update on IL-23 and IL-17 inhibitors", Cutis, 99, pp.123~127 (2017)
- Machado NP, "The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis", Clinics(Sao Paulo), 68, pp.1189~1196 (2013)
- Park JJ, "A case of tumor necrosis factor-alpha inhibitorsinduced pustular psoriasis", Ann Dermatol, 22, pp.212~215 (2010)
- Méry-Bossard L, "New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases", J Eur Acad Dermatol Venereol, 31, pp.181~186 (2017)
- Nieto-Benito LM, "New-onset vitiligo during treatment with secukinumab : report of two cases and review of the literature", Clin Drug Investig, 40, pp.1089~1091 (2020)
- Palazzo G, "Resolution of post-adalimumab viti ligo with secukinumab in a patient with psoriasis vulgaris", Oxf Med Case Reports, 2020, pp.omz134~ (2020)
- Speeckaert R, "IL-17A is not a treatment target in progressive vitiligo", Pigment Cell Melanoma Res, 32, pp.842~847 (2019)
- Chatterjee S, "A quantitative increase in regulatory T cells controls development of vitiligo", J Invest Dermatol, 134, pp.1285~1294 (2014)
- Moretti S, "New insights into the pathogenesis of vitiligo : imbalance of epidermal cytokines at sites of lesions", Pigment Cell Res, 15, pp.87~92 (2002)
- Yang L, "Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes : a pivotal role of CD8+ cytotoxic t lymphocytes in vitiligo", Acta Derm Venereol, 95, pp.664~670 (2015)
- Richmond JM, "T-cell positioning by chemokines in autoimmune skin diseases", Immunol Rev, 289, pp.186~204 (2019)
- Wang CQF, "IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis : potential relevance to psoriasis", J Invest Dermatol, 133, pp.2741~2752 (2013)